Aeon Biopharma, INC 8-K filings

AEON Biopharma reported Q2 2026 results, highlighting a $15.3 million financing with milestone warrants and continued progress in developing its ABP-450 biosimilar to BOTOX.

AEON Biopharma, Inc. announced the completion of its public offering, including the partial exercise of an over-allotment option, raising additional capital.

Aeon Biopharma announced the pricing of its underwritten public offering, raising up to $13.75 million with potential for additional future funding through milestone warrants.

AEON Biopharma reported Q1 2026 results, highlighting positive FDA feedback on its biosimilar development strategy for ABP-450 and a significant reduction in outstanding debt.

AEON Biopharma reported a 2025 net loss while highlighting positive FDA feedback and analytical data for its ABP-450 Botox biosimilar, plus a $6M PIPE and note exchange to strengthen liquidity.

AEON Biopharma shareholders approve key transactions, including a debt-reducing note exchange and a PIPE financing, while the company progresses its ABP-450 biosimilar with a recent FDA meeting.

AEON Biopharma, Inc. unveils its strategy to introduce ABP-450 as a biosimilar to BOTOX, aiming for full label parity and significant market disruption by 2030.

AEON Biopharma announced a definitive agreement with Daewoong Pharmaceutical to exchange $15 million in convertible notes for new equity, a $1.5 million new note, and warrants, significantly deleveraging the company.

AEON Biopharma, Inc. announced positive biosimilarity data for ABP-450, secured new financing, and simplified its balance sheet, positioning for an accelerated FDA approval pathway.

AEON Biopharma announced its third quarter 2025 financial results, positive ABP-450 biosimilarity data, and strategic financing to strengthen its balance sheet and accelerate its program.

AEON Biopharma announced a private placement of common stock and warrants, alongside a convertible note exchange with Daewoong, to raise capital and restructure debt.

AEON Biopharma outlines its strategy to enter the U.S. therapeutic neurotoxin market with ABP-450 via a biosimilar pathway, targeting all 12 BOTOX indications.

AEON Biopharma announced a net loss for Q2 2025 while progressing its ABP-450 biosimilar toward key FDA meetings.

AEON Biopharma, Inc. announced the successful election of two Class II directors and the ratification of KPMG LLP as its independent auditor at its Annual Meeting of Stockholders held on June 13, 2025.

AEON Biopharma is developing ABP-450, a biosimilar to Botox, targeting the full range of Botox's approved therapeutic indications and addressing cost-related barriers in the market.

AEON Biopharma announced its Q1 2025 financial results, highlighting progress in its ABP-450 biosimilar development program and a leadership change.

AEON Biopharma's plan to regain compliance with NYSE American listing standards has been accepted, granting the company until August 3, 2026, to meet the requirements.

AEON Biopharma appoints Robert Bancroft as its new CEO, President, and a member of the Board, effective April 29, 2025.

AEON Biopharma announces the appointment of Jost Fischer as Interim President and CEO and Jennifer Sy as Chief Accounting Officer, effective April 4, 2025.

AEON Biopharma announces that Marc Forth is stepping down as President and CEO, with Jost Fischer, Chairman of the Board, appointed as Interim CEO, effective April 4, 2025.

AEON Biopharma reports its financial results for Q4 and full year 2024, highlighting progress in its ABP-450 biosimilar development program and a successful public offering.

AEON Biopharma is advancing its PrabotulinumtoxinA as a biosimilar to Botox, targeting a potential $2.7 billion US therapeutic market.

AEON Biopharma implements a 1-for-72 reverse stock split to boost its stock price and maintain compliance with NYSE American listing requirements.

AEON Biopharma received a notice from NYSE American regarding non-compliance with continued listing standards due to a stockholders' equity deficit.

AEON Biopharma successfully priced and closed a $20 million public offering to fund the development of its botulinum toxin complex, ABP-450.

AEON Biopharma has priced a $20 million public offering to support the development of its botulinum toxin biosimilar, ABP-450.

Aeon Biopharma has amended its bylaws to lower the quorum requirement for shareholder meetings from a majority to 33.34% of voting power.

AEON Biopharma reported its Q3 2024 financial results and provided a corporate update, highlighting progress in its biosimilar development program for ABP-450.

AEON Biopharma is advancing its PrabotulinumtoxinA as a biosimilar to Botox, aiming for approval across all 12 therapeutic indications and a share of the $2.5 billion US market.

AEON Biopharma reported its second quarter 2024 financial results and provided a corporate update, highlighting progress in its biosimilar development program for ABP-450.